The present invention relates to a base form, a hydrate form or a solvate in combination with prednisone or prednisolone for use as a treatment for prostate cancer, particularly metastatic prostate cancer, especially for patients not responsive to taxane-based treatment. It relates to compounds of formula (I) which may be in the form.